Summary

With the introduction of several new antiplatelet and anticoagulant agents that have multiple actions and interactions, selection of the optimal antithrombotic has become quite complex. This article discusses direct Xa inhibitors, direct thrombin inhibitors, GP IIb/IIIa inhibitors, adenosine diphosphate inhibitors, as well as novel targets for antithrombotic therapy.